--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About PLRX20260417P1.5
Pharmaceutical
Pliant Therapeutics, Inc., was incorporated in June 2015 under the laws of the State of Delaware. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of new therapies for the treatment of fibrosis. Their initial focus was on treating fibrosis by inhibiting integrin-mediated TGF-β activation. Leveraging their deep understanding of fibrosis biology, as well as their expertise in medicinal chemistry and translational medicine, the company has developed a suite of proprietary tools designed to quickly and effectively discover and reduce the risk of product candidates. Their wholly-owned lead drug candidate, PLN-74809, is an oral small molecule dual selective inhibitor of integrin, which the company is developing for the treatment of idiopathic pulmonary fibrosis or IPF, primary sclerosing cholangitis or PSC.
